Cat. #161752
DLKP-A10 cell line
Cat. #: 161752
Organism: Human
Tissue: Lung
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Martin Clynes
Institute: Dublin City University
Primary Citation: Clary et. al. Biochemical Pharmacology, 1997 53(10): 1493-1502. PMID: 9260877
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: DLKP-A10 cell line
- Cancer: Lung cancer
- Research fields: Cancer
- Parental cell: DLKP cell line
- Organism: Human
- Tissue: Lung
- Disease: Cancer
- Morphology: Monolayer
- Crispr: No
- Products or characteristics of interest: The cell line exhibits various levels of resistance to chemotherapeutic agents
- Description: DLKP-A10 is a drug-resistant subpopulation of DLKP squamous carcinoma cell line. It overexpresses the MDR associated P-glycoprotein efflux pump.
- Production details: DLKP-A was established by continuous exposure of the DLKP cells (pDLKP) to escalating concentrations of Adr (Step 1: 0.05 ?g/mL0.8 ?g/mL Adr for 11 months, Step 2: 0.8 ?g/mL1.75 ?g/mL for 3 months and Step 3: 1.75 ?g/mL2.1 ?g/mL for 3 months)
Handling
- Volume: Frozen
- Growth medium: DMEM-F12 medium supplemented with 5% FBS and 1% L-glutamine
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Clary et. al. Biochemical Pharmacology, 1997 53(10): 1493-1502. PMID: 9260877
- Efeoglu et. al. Biomolecules. 2022 Oct 1,12(10):1401. PMID: 36291610
